Adrian Woolfson, Sangamo’s Executive Vice President of Research and Development, recently spoke to GEN EDGE about Sangamo’s progress and aspirations in gene therapy, gene editing, and how he is pinning big hopes on zinc fingers, which make up the first proven genome editing technology pioneered by the Bay-Area-based biotech . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge